Header Logo

Connection

Peter Friedmann to Opioid-Related Disorders

Back to Details
This is a "connection" page, showing publications Peter Friedmann has written about Opioid-Related Disorders.
Peter Friedmann
Connection Strength
17.578
Opioid-Related Disorders
  1. Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
    View in: PubMed
    Score: 0.555
  2. Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 02 12; 19(1):10.
    View in: PubMed
    Score: 0.538
  3. Michener PS, Knee A, Wilson D, Boama-Nyarko E, Friedmann PD. Association of random and observed urine drug screening with long-term retention in opioid treatment programs. Drug Alcohol Depend. 2024 Feb 01; 255:111067.
    View in: PubMed
    Score: 0.533
  4. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
    View in: PubMed
    Score: 0.530
  5. Pivovarova E, Taxman FS, Boland AK, Smelson DA, Lemon SC, Friedmann PD. Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. J Subst Use Addict Treat. 2023 04; 147:208950.
    View in: PubMed
    Score: 0.500
  6. Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
    View in: PubMed
    Score: 0.486
  7. Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. J Acquir Immune Defic Syndr. 2022 08 15; 90(5):546-552.
    View in: PubMed
    Score: 0.485
  8. Nolte K, Romo E, Stopka TJ, Drew A, Dowd P, Del Toro-Mejias L, Bianchet E, Friedmann PD. "I've been to?more?of my friends'?funerals?than?I've been to my friends' weddings": Witnessing and responding to overdose in rural Northern New England. J Rural Health. 2023 01; 39(1):197-211.
    View in: PubMed
    Score: 0.472
  9. Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
    View in: PubMed
    Score: 0.471
  10. Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
    View in: PubMed
    Score: 0.470
  11. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.467
  12. Peacock-Chambers E, Paterno MT, Kiely D, Fioroni T, Byatt N, Friedmann PD. Engagement in perinatal outpatient services among women in recovery from opioid use disorders. Subst Abus. 2021; 42(4):1022-1029.
    View in: PubMed
    Score: 0.442
  13. Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.
    View in: PubMed
    Score: 0.424
  14. Peacock-Chambers E, Feinberg E, Senn-McNally M, Clark MC, Jurkowski B, Suchman NE, Byatt N, Friedmann PD. Engagement in Early Intervention Services Among Mothers in Recovery From Opioid Use Disorders. Pediatrics. 2020 02; 145(2).
    View in: PubMed
    Score: 0.407
  15. Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics. 2020 01; 17(1):55-69.
    View in: PubMed
    Score: 0.405
  16. Paterno MT, Jablonski L, Klepacki A, Friedmann PD. Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes. J Obstet Gynecol Neonatal Nurs. 2019 Sep; 48(5):495-506.
    View in: PubMed
    Score: 0.393
  17. Stopka TJ, Jacque E, Kelso P, Guhn-Knight H, Nolte K, Hoskinson R, Jones A, Harding J, Drew A, VanDonsel A, Friedmann PD. The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance. Prev Med. 2019 11; 128:105740.
    View in: PubMed
    Score: 0.389
  18. Andrews CM, Abraham AJ, Grogan CM, Westlake MA, Pollack HA, Friedmann PD. Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs. Am J Public Health. 2019 03; 109(3):434-436.
    View in: PubMed
    Score: 0.379
  19. Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486.
    View in: PubMed
    Score: 0.376
  20. Abraham AJ, Andrews CM, Grogan CM, Pollack HA, D'Aunno T, Humphreys K, Friedmann PD. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatr Serv. 2018 04 01; 69(4):448-455.
    View in: PubMed
    Score: 0.351
  21. Friedmann PD, Dunn KE, Nunes EV, O'Brien CP. Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. J Subst Abuse Treat. 2018 02; 85:31-33.
    View in: PubMed
    Score: 0.350
  22. Friedmann PD, Suzuki J. More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addict Sci Clin Pract. 2017 11 15; 12(1):29.
    View in: PubMed
    Score: 0.349
  23. Soares WE, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV, O'Brien CP, Friedmann PD. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. J Subst Abuse Treat. 2018 02; 85:66-69.
    View in: PubMed
    Score: 0.337
  24. Friedmann PD, Wilson D, Hoskinson R, Poshkus M, Clarke JG. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. J Subst Abuse Treat. 2018 02; 85:45-48.
    View in: PubMed
    Score: 0.336
  25. Friedmann PD, Andrews CM, Humphreys K. How ACA Repeal Would Worsen the Opioid Epidemic. N Engl J Med. 2017 Mar 09; 376(10):e16.
    View in: PubMed
    Score: 0.333
  26. Friedmann PD, Wilson D, Nunes EV, Hoskinson R, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat. 2018 02; 85:61-65.
    View in: PubMed
    Score: 0.332
  27. Grogan CM, Andrews C, Abraham A, Humphreys K, Pollack HA, Smith BT, Friedmann PD. Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications. Health Aff (Millwood). 2016 12 01; 35(12):2289-2296.
    View in: PubMed
    Score: 0.327
  28. Friedmann PD, Wilson D, Knudsen HK, Ducharme LJ, Welsh WN, Frisman L, Knight K, Lin HJ, James A, Albizu-Garcia CE, Pankow J, Hall EA, Urbine TF, Abdel-Salam S, Duvall JL, Vocci FJ. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015 Mar; 50:50-8.
    View in: PubMed
    Score: 0.282
  29. Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014 Feb; 71(1):43-60.
    View in: PubMed
    Score: 0.262
  30. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014 Feb; 49(1):230-48.
    View in: PubMed
    Score: 0.259
  31. Friedmann PD, Schwartz RP. Just call it "treatment". Addict Sci Clin Pract. 2012 Jun 09; 7:10.
    View in: PubMed
    Score: 0.240
  32. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010 Jul; 37(3):322-37.
    View in: PubMed
    Score: 0.192
  33. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007; 26(2):1-2.
    View in: PubMed
    Score: 0.164
  34. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 Nov; 20(11):1038-41.
    View in: PubMed
    Score: 0.152
  35. Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 01; 185(6):624-633.
    View in: PubMed
    Score: 0.147
  36. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005 Sep; 82(3):411-9.
    View in: PubMed
    Score: 0.147
  37. Morenz AM, Nance RM, Mixson LS, Feinberg J, Smith G, Korthuis PT, Pho MT, Jenkins WD, Friedmann PD, Stopka TJ, Fanucchi LC, Miller WC, Go VF, Westergaard R, Seal DW, Zule WA, Crane HM, Delaney JA, Tsui JI. Barriers to accessing medications for opioid use disorder among rural individuals. Int J Drug Policy. 2025 Jun; 140:104805.
    View in: PubMed
    Score: 0.146
  38. Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 Apr 01; 8(4):e255340.
    View in: PubMed
    Score: 0.146
  39. Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
    View in: PubMed
    Score: 0.142
  40. Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.
    View in: PubMed
    Score: 0.140
  41. Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 09 03; 7(9):e2434704.
    View in: PubMed
    Score: 0.140
  42. Soares WE, Schoenfeld E, Friedmann PD. Precipitated Withdrawal in the Era of Street Fentanyl-The Important Thing Is to Not Stop Questioning. JAMA Netw Open. 2024 09 03; 7(9):e2435857.
    View in: PubMed
    Score: 0.140
  43. Williams AR, Mauro CM, Chiodo L, Huber B, Cruz A, Crystal S, Samples H, Nowels M, Wilson A, Friedmann PD, Remien RH, Olfson M. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug Alcohol Depend. 2024 Oct 01; 263:112389.
    View in: PubMed
    Score: 0.139
  44. Fredericksen RJ, Mixson LS, Estadt AT, Leichtling G, Bresett J, Zule W, Walters SM, Friedmann PD, Romo E, Whitney BM, Delaney JAC, Crane HM, Tsui JI, Young A, Seal D, Stopka TJ. Barriers to retention in inpatient and residential drug treatment among persons who use opioids and/or injection drugs living in the rural U.S. J Subst Use Addict Treat. 2024 Oct; 165:209453.
    View in: PubMed
    Score: 0.139
  45. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
    View in: PubMed
    Score: 0.139
  46. Evans SK, Ober AJ, Korn AR, Peltz A, Friedmann PD, Page K, Murray-Krezan C, Huerta S, Ryzewicz SJ, Tarhuni L, Nuckols TK, E Watkins K, Danovitch I. Contextual barriers and enablers to establishing an addiction-focused consultation team for hospitalized adults with opioid use disorder. Addict Sci Clin Pract. 2024 04 26; 19(1):31.
    View in: PubMed
    Score: 0.137
  47. Sibley AL, Klein E, Cooper HLF, Livingston MD, Baker R, Walters SM, Gicquelais RE, Ruderman SA, Friedmann PD, Jenkins WD, Go VF, Miller WC, Westergaard RP, Crane HM. The relationship between felt stigma and non-fatal overdose among rural people who use drugs. Harm Reduct J. 2024 04 06; 21(1):77.
    View in: PubMed
    Score: 0.136
  48. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
    View in: PubMed
    Score: 0.135
  49. Stopka TJ, Estadt AT, Leichtling G, Schleicher JC, Mixson LS, Bresett J, Romo E, Dowd P, Walters SM, Young AM, Zule W, Friedmann PD, Go VF, Baker R, Fredericksen RJ. Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study. Soc Sci Med. 2024 04; 346:116660.
    View in: PubMed
    Score: 0.135
  50. Rains A, Sibley AL, Levander XA, Walters SM, Nolte K, Colston DC, Piscalko HM, Go VF, Friedmann PD, Seal DW. "I would do anything but that": Attitudes towards sex work among rural people who use drugs. Int J Drug Policy. 2023 Dec; 122:104237.
    View in: PubMed
    Score: 0.132
  51. Tsui JI, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, Young AM, Cooper HLF, Friedmann PD, Stopka TJ, de Gijsel D, Miller WC, Go VF, Westergaard R, Brown R, Seal DW, Zule WA, Feinberg J, Smith GS, Mixson LS, Fredericksen R, Crane HM, Delaney JA. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend. 2023 09 01; 250:110911.
    View in: PubMed
    Score: 0.130
  52. Church B, Clark R, Mohn W, Potee R, Friedmann P, Soares WE. Methadone Induction for a Patient With Precipitated Withdrawal in the Emergency Department: A Case Report. J Addict Med. 2023 May-Jun 01; 17(3):367-370.
    View in: PubMed
    Score: 0.124
  53. Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
    View in: PubMed
    Score: 0.121
  54. Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Chan Osilla K, Ryzewicz S, Huerta S, Mazer MW, Leamon I, Messineo G, Watkins KE, Nuckols T, Danovitch I. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder. Addict Sci Clin Pract. 2022 07 28; 17(1):39.
    View in: PubMed
    Score: 0.121
  55. Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, Fredericksen R, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Rudolph AE, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Young AM, Zule WA, Delaney JAC, Tsui JI, Crane HM. The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. Addict Sci Clin Pract. 2022 07 26; 17(1):38.
    View in: PubMed
    Score: 0.121
  56. McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis. 2002; 21(2):93-102.
    View in: PubMed
    Score: 0.116
  57. Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
    View in: PubMed
    Score: 0.109
  58. Nolte K, Drew AL, Friedmann PD, Romo E, Kinney LM, Stopka TJ. Opioid initiation and injection transition in rural northern New England: A mixed-methods approach. Drug Alcohol Depend. 2020 12 01; 217:108256.
    View in: PubMed
    Score: 0.106
  59. Peacock-Chambers E, Leyenaar JK, Foss S, Feinberg E, Wilson D, Friedmann PD, Visintainer P, Singh R. Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome. J Dev Behav Pediatr. 2019 Jul/Aug; 40(6):441-450.
    View in: PubMed
    Score: 0.098
  60. Abraham AJ, Smith BT, Andrews CM, Bersamira CS, Grogan CM, Pollack HA, Friedmann PD. Changes in State Technical Assistance Priorities and Block Grant Funds for Addiction After ACA Implementation. Am J Public Health. 2019 06; 109(6):885-891.
    View in: PubMed
    Score: 0.096
  61. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018 08; 91:57-68.
    View in: PubMed
    Score: 0.091
  62. Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP. Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics. 2018 04; 13(2):160-172.
    View in: PubMed
    Score: 0.089
  63. Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. J Subst Abuse Treat. 2017 10; 81:66-72.
    View in: PubMed
    Score: 0.086
  64. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O'Brien CP. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat. 2018 02; 85:49-55.
    View in: PubMed
    Score: 0.084
  65. Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction. 2017 Aug; 112(8):1440-1450.
    View in: PubMed
    Score: 0.084
  66. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42.
    View in: PubMed
    Score: 0.078
  67. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglione J, Schwartz RP, Gordon MS, Friedmann PD. Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016; 37(1):127-33.
    View in: PubMed
    Score: 0.077
  68. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7.
    View in: PubMed
    Score: 0.072
  69. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013 May-Jun; 53(3):273-81.
    View in: PubMed
    Score: 0.064
  70. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013 Aug; 45(2):222-6.
    View in: PubMed
    Score: 0.063
  71. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med. 2012 Sep; 6(3):179-85.
    View in: PubMed
    Score: 0.061
  72. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, Rich JD. A randomized trial of methadone initiation prior to release from incarceration. Subst Abus. 2012; 33(1):19-29.
    View in: PubMed
    Score: 0.058
  73. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012; 33(1):48-59.
    View in: PubMed
    Score: 0.058
  74. Cioe PA, Friedmann PD, Stein MD. Erectile dysfunction in opioid users: lack of association with serum testosterone. J Addict Dis. 2010 Oct; 29(4):455-60.
    View in: PubMed
    Score: 0.053
  75. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010 Sep; 39(2):157-66.
    View in: PubMed
    Score: 0.052
  76. Estadt AT, Kline D, Miller WC, Feinberg J, Hurt CB, Mixson LS, Friedmann PD, Lowe K, Tsui JI, Young AM, Cooper H, Korthuis PT, Pho MT, Jenkins W, Westergaard RP, Go VF, Brook D, Smith G, Rice DR, Lancaster KE. Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities. Harm Reduct J. 2024 Nov 29; 21(1):214.
    View in: PubMed
    Score: 0.036
  77. Ballard AM, Kesich Z, Crane HM, Feinberg J, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Zule WA, Young AM, Cooper HL. Rural houselessness among people who use drugs in the United States: Results from the National Rural Opioid Initiative. Drug Alcohol Depend. 2025 Jan 01; 266:112498.
    View in: PubMed
    Score: 0.035
  78. Prusaczyk B, Tilmon S, Landman J, Seibert D, Colston DC, Westergaard R, Cooper H, Feinberg J, Friedmann PD, Go VF, Khoury D, Korthius T, Mixson S, Moellner A, Nolte K, Smith G, Young A, Pho MT, Jenkins W. Barriers to Healthcare and Social Service Utilization Among Rural Older Adults Who Use Drugs. J Appl Gerontol. 2024 Dec; 43(12):1977-1984.
    View in: PubMed
    Score: 0.034
  79. Rudolph AE, Nance RM, Bobashev G, Brook D, Akhtar W, Cook R, Cooper HL, Friedmann PD, Frost SDW, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Ruderman SA, Seal DW, Stopka TJ, Westergaard RP, Young AM, Zule WA, Tsui JI, Crane HM, Whitney BM, Delaney JAC. Evaluation of respondent-driven sampling in seven studies of people who use drugs from rural populations: findings from the Rural Opioid Initiative. BMC Med Res Methodol. 2024 Apr 23; 24(1):94.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.